Healthcare

Telix Pharmaceuticals Limited (ASX:TLX)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 6.35-0.25 (3.788%)

(as on 2021-12-01 20:57:48 AEDT)

Market Cap : AUD 1.81 B

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
6.6 6.55 6.35 6.330L 6.720 H 3.260L 7.650 H
Last Trade 6.35
Change% -3.7879
52 W H/L 7.650/3.260
EBITDA -52.599 M
NPAT After Abnormal Items -44.887 M
Equity 79.016 M
ROE% -47.58%
Total Liabilities 78.805 M
Total Revenue 18.867 M
Cash and Cash Equivalents 77.945 M

Stock Information

Share price 6.35
Market Cap 1.81 B
Price/Gross Cash Flow -46.50
Dividend Yield Excluding Special 0.00%
Ending Shares 280.405 M
52-Week Range 7.650-3.260
P/E ratio 0.000
Sector P/E --
EPS -17.45
EV/EBITDA --
Net Profit Margin (%) -803.33%
Gross Cash Flows Per Share -0.09
Net Gearing -95.85%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.07
Sales Per Share 0.02
Book Value Per Share 0.28

Announcements

Heading Date/Time
Investor Presentation - November 2021  16/11/2021 8:17AM
Australian TGA Approves Illuccix for Prostate Cancer Imaging  02/11/2021 9:29AM
Activities Report and App 4C - September 2021 quarter  21/10/2021 8:19AM
Release of Shares from Voluntary Escrow  21/10/2021 8:19AM
IPAX-1 Presentation at Congress of Neurological Surgeons  20/10/2021 8:26AM
Cleansing Notice under S708A Corporations Act  29/09/2021 8:24AM
Appendix 3Y - Change of Directors Interest Notice - McCann  29/09/2021 8:24AM
Appendix 3Y - Change of Directors Interest Notice - Nelson  29/09/2021 8:23AM
Application for quotation of securities - TLX  29/09/2021 8:23AM
$12.1M R&D Tax Refund, Overseas Finding Increased to $139M  28/09/2021 8:25AM
FDA Extends New Drug Application Review Period for Illuccix  23/09/2021 8:39AM
Telix Supporting Amgen PSMA-Targeting Therapy Trial  15/09/2021 8:23AM
NCCN Guidelines updated to include PSMA-PET Imaging  14/09/2021 10:00AM
FDA Approves Phase II Kidney Cancer Therapy Study  14/09/2021 8:22AM
Telix and Radius sign Distribution Agreement for Italy  13/09/2021 8:21AM
Japanese Prostate Cancer Imaging Study Completes Enrolment  09/09/2021 8:23AM
Change in substantial holding  01/09/2021 7:15PM
Collaboration with Lightpoint Medical on Radioguided Surgery  23/08/2021 8:16AM
Results Presentation and Shareholder Update 1H 2021  19/08/2021 8:07AM
App 4D and Report for Half-Year Ended 30 June 2021  19/08/2021 8:07AM
GenesisCare Collaboration Expands Prostate Cancer Activity  19/08/2021 8:07AM
Telix and Merck pan-cancer clinical collaboration  18/08/2021 9:26AM
Two studies explore TLX assets in Breast Cancer Theranostics  18/08/2021 8:54AM
TLX66 in Phase II Academic Study of Pediatric Leukemia  17/08/2021 8:19AM
Telix H1 2021 Results and Company Update Conference Call  11/08/2021 8:18AM
1st Patient Dosed in CUPID study of TLX592  05/08/2021 8:23AM
Telix Seneffe Production Facility - Progress Update  30/07/2021 8:14AM
App 4C and Activities Report for June 2021 Quarter  22/07/2021 8:18AM
Notification of cessation of securities - TLX  22/07/2021 8:16AM

Similar Companies

Related Articles

Load More

About Company

Telix Pharmaceuticals Limited (ASX: TLX) under health care sector is engaged into the commercializing and development of molecularly targeted radiation (MTR) products for the treatment of cancer. It is based out of Flemington road, North Melbourne, Australia. The company’s incorporation year was 2017 and is categorized as a bio-pharmaceutical company. Products such as TLX-250, TLX-591 and TLX-101 are included in company’s MTR range.

Corporate Information

company address Suite 401, 55 Flemington Road, NORTH MELBOURNE, VIC, AUSTRALIA, 3051

company phone03 3093 3897

company websitehttp://www.telixpharma.com

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/12/2020 -- 0.000 0.00%
30/12/2019 -- 0.000 0.00%
30/12/2018 -- 0.000 0.00%
30/12/2017 -- 0.000 0.00%
30/09/2000 -- 0.000 --
30/09/1999 -- 0.000 --

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2022-08-18 2022
Report (Annual) 2022-02-25 2022
Report (Prelim) 2022-02-25 2022

Financials

Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/09/2000
Trading Revenue 3.278 M 3.485 M 195,142 -- --
Other Revenue 15.589 M 11.897 M 11.645 M 403,467 0
Total Revenue 18.867 M 15.382 M 11.84 M 403,467 0
Interest Income 67,000 98,000 332,751 38,980 5,000
Interest Expenses -1.175 M -2.408 M -29,018 -9,401 0
Expenses -53.521 M -39.958 M -27.851 M -6.806 M -502,000
EBITDA -34.654 M -24.576 M -16.011 M -6.403 M -502,000
Depreciation and Amortization -4.882 M -4.236 M -6,968 -3,793 0
Depreciation -777,000 -323,000 -200 -253 0
Amortisation -4.105 M -3.913 M -6,768 -3,540 0
EBIT -39.536 M -28.812 M -16.018 M -6.407 M -502,000
Pre Tax Profit -40.644 M -31.122 M -15.714 M -6.377 M -497,000
Tax Expense 3.048 M 3.255 M 1.884 M 0 0
Net Profit After Tax -37.596 M -27.867 M -13.83 M -6.377 M -497,000
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items -7.291 M 0 0 0 0
Reported Net Profit After Abnormal Items -44.887 M -27.867 M -13.83 M -6.377 M -497,000
Ending Shares 280.405 M 253.28 M 218.366 M 197.438 M 38.665 M
Weighted Average Shares 257.271 M 233.437 M 202.124 M 127.994 M 38.665 M
EPS After Abnormal Items (cents) -17.45 -11.94 -6.84 -4.98 -1.29
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/09/2000
Total Current Assets 93.628 M 58.679 M 35.856 M 49.545 M 3.049 M
Total Non Current Assets 64.193 M 43.929 M 40.852 M 1.549 M 6.345 M
Total Assets 157.821 M 102.608 M 76.708 M 51.094 M 9.394 M
Total Current Liabilities 19.956 M 10.625 M 8.242 M 1.468 M 352,000
Total Non Current Liabilities 58.849 M 21.902 M 15.562 M 332,489 0
Total Liabilities 78.805 M 32.527 M 23.804 M 1.801 M 352,000
Net Assets 79.016 M 70.081 M 52.904 M 49.293 M 9.042 M
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/09/2000
Net Operating Cash 1.96 M -23.333 M -20.749 M -6.032 M 0
Net Invested Cash -1.091 M -468,000 -2.693 M -1,260 0
Net Financing Cash Flows 34.117 M 42.723 M -869,354 54.792 M 0
Beginning Cash 44.598 M 25.771 M 48.759 M 0 0
End Cash Position 77.945 M 44.598 M 25.771 M 48.759 M 0
Exchange Rate Adjustments -1.639 M -95,000 1.322 M 0 0
Other Cash Adjustments 0 0 1,476 0 0
Ending Cash 77.945 M 44.598 M 25.771 M 48.759 M 0

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK